8月21日晚，先声药业（02096.HK）发布2025年中期业绩报告。期内实现营收35.85亿元，同比增长15.1%；归属于公司权益股东的利润达6.04亿元，同比大幅增长32.2%，经调整后净利润6.51亿元，增幅21.1%。其中，创新药业务表现尤为亮眼，收入达27.76亿元，同比增长26.0%，占总收入的77.4%，成为业绩增长的主要驱动力。三大治疗领域全面开花，神经科学与抗肿瘤领域增长强劲从...
Source Link8月21日晚，先声药业（02096.HK）发布2025年中期业绩报告。期内实现营收35.85亿元，同比增长15.1%；归属于公司权益股东的利润达6.04亿元，同比大幅增长32.2%，经调整后净利润6.51亿元，增幅21.1%。其中，创新药业务表现尤为亮眼，收入达27.76亿元，同比增长26.0%，占总收入的77.4%，成为业绩增长的主要驱动力。三大治疗领域全面开花，神经科学与抗肿瘤领域增长强劲从...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.